Last reviewed · How we verify
NCT07273032
Clinical Application Research of Combined Therapy in ERAS for Accelerated Orthopedic Rehabilitation
Phase 4 trial testing Blank control group in Meniscus Injury in 120 participants. Not yet recruiting.
31 December 2025
Quick facts
| Lead sponsor | Ningbo Medical Center Lihuili Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | supportive care |
| Enrollment | 120 |
| Start date | 30 December 2025 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2026 |
Drugs / interventions tested
- Blank control group
- Henggu Bone Injury Healing Agent Intervention Group — full drug profile →
- Lower limb rehabilitation training system intervention group
Conditions studied
- Meniscus Injury — all drugs for Meniscus Injury →
Sponsor
Ningbo Medical Center Lihuili Hospital
Who can join
Adults 20 to 65, any sex, with Meniscus Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The double-blind method is adopted.Case selection Patients who underwent meniscus repair surgery under knee arthroscopy at Li Huili Hospital Affiliated to Ningbo University, the 906th Hospital of the People's Liberation Army (Joint Logistic Support Force of the Chinese People's Liberation Army), and Yangming Hospital Affiliated to Ningbo University (Yuyao People's Hospital), with ages set at 20 to 65 years old, are planned to be included in a sample size of 120 cases based on previous research experience, divided into 4 groups. They were respectively: the blank control group, the Henggu Bone Injury Healing Agent intervention group, the lower limb rehabilitation training system intervention group, and the Henggu Bone injury Healing agent combined with the lower limb rehabilitation training system intervention group, with 30 cases in each group. Grouping was conducted using a double-blind method, with random grouping carried out by a third-party organization. 1. Inclusion criteria: (1) The patient is conscious and aware of the content of this study; (2) Those with good compliance; (3) Possess good language communication skills. 2. Exclusion criteria: (1) Severely obese patients; (2) People with cognitive dysfunction; (3) Those with relevant serious complications; (4) Those with severe heart, liver or kidney insufficiency. 3. Exclusion criteria: Those who received intervention with other anti-inflammatory and analgesic drugs after the operation. Criteria for terminating the study: Postoperative complications such as joint infection and deep vein thrombosis of the lower extremities occur after the operation. Blank control group: No intervention measures Lower limb rehabilitation training system intervention group: Received rehabilitation system intervention after the operation Henggu Bone Injury Healing Agent Intervention Group: Take Henggu Bone Injury Healing Agent after the operation The combined intervention group: After the operation, they took Henggu bone injury Healing Agent and received rehabilitation system intervention The knee joint function and pain scores of each group, the implementation of the recovery plan, remote guidance of the rehabilitation system (applicable to the intervention group), and the duration of drug use: a total of 6 weeks of Henggu Bone Injury Healing Agent were evaluated at 1 day, 4 weeks, 3 months, and 6 months after the operation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07273032
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Meniscus Injury
Currently open trials in the same condition.
- NCT06870825 — Assessment of Quadriceps Femoris Muscle Function in Patients After Arthroscopic Knee Surgery in Outpatient Rehabilitatio · NA · active not recruiting
- NCT06906783 — Transtibial Pull Out Method Versus Suture Anchor Method for Meniscus Extrusion · NA · recruiting
Other Ningbo Medical Center Lihuili Hospital trials
Trials by the same sponsor.
- NCT07572708 — Transcutaneous Electrical Acustimulation (TEA) for the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD) · NA · not yet recruiting
- NCT07368023 — A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoin · not yet recruiting
- NCT07310836 — A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoin · not yet recruiting
- NCT06982664 — Effect of Preserving the Left Colic Artery on Proximal Bowel Perfusion · NA · not yet recruiting
- NCT06804733 — Efficacy of Individualized Aerobic Exercise Training in Patients With Inflammatory Bowel Disease · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07273032 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ningbo Medical Center Lihuili Hospital
- Last refreshed: 9 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07273032.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing